Company record · BIIB · Biological Products, (No Diagnostic Substances)
Biogen
The principal financial officer who signed Biogen's latest annual report, the 10-K filed February 6, 2026, is Robin C. Kramer.
The record holds the CFO signature on Biogen's 10-K filed February 6, 2026 and no Form 8-K CFO change.
The CFO seat
Computed from the records below: a move filed on or after the 10-K replaces the 10-K's signature.
| Status | Filled |
|---|---|
| Officer | Robin C. Kramer |
| Title as printed | Executive Vice President and Chief Financial Officer (principal financial officer) |
| Basis | Verified February 6, 2026: the 10-K signature block (sec.gov) |
Seat timeline
1Every verified record for this seat, newest first, dated as the filing states it.
2026-02-0610-K signature
Robin C. Kramer signed the annual report as Executive Vice President and Chief Financial Officer (principal financial officer)
10-K filed February 6, 2026 · sec.gov
“/S/ ROBIN C. KRAMER Executive Vice President and Chief Financial Officer (principal financial officer)”
Company
| Ticker | BIIB |
|---|---|
| SEC CIK | 0000875045 |
| Industry (SIC) | Biological Products, (No Diagnostic Substances) (2836) |
| Roster note | The DEF 14A filed 2026-04-28 also names Robin C. Kramer alongside a Chief Financial Officer title. An 8-K with Item 5.02 was filed on 2026-03-11, after this 10-K; any CFO change it reports is tracked on the moves record. |
Same industry on the record
8Other companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
Allogene Therapeutics, Inc.ALLO
Departure disclosed · Geoffrey Parker · no successor on the record yet
Armata Pharmaceuticals, Inc.ARMP
CFO: David House · effective July 17, 2026
Atara Biotherapeutics, Inc.ATRA
Interim CFO: Kevin G. Sarney · effective June 26, 2026
Caribou Biosciences, Inc.CRBU
Departure disclosed · Sriram Ryali · no successor on the record yet
ImageneBio, Inc.IMA
CFO: Yanina Grant-Huerta · effective July 20, 2026
IRulya Therapeutics Inc.QNCX
CFO: John Militello · effective not stated in the source
Jasper Therapeutics, Inc.JSPR
Interim CFO: Jeet Mahal · effective October 9, 2026
Kalaris Therapeutics, Inc.KLRS
CFO: Liisa Bayko · effective July 20, 2026
This record covers what the tracked filings state; it is not a complete history of the company's finance leadership. Spot an error? Send a correction.